ReviewNeuro-oncology2016

Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.

Terri S Armstrong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.